Michele T. Del Vecchio
Expertise in
2
conditions

Michele T. Del Vecchio

Milan, IT 
Expertise in
2
conditions
Milan, IT 

Overview

Michele Del Vecchio practices practicing medicine in Milan, Italy.

Del Vecchio is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Melanoma, Metastatic Brain Tumor, Brain Tumor, and Metastatic Uveal Melanoma.

They are actively involved in clinical research, co-authoring 130 peer reviewed articles and participating in 4 clinical trials.

Locations

Milan, Italy
Other Locations
Naples, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

NEOadjuvant Plus Adjuvant Therapy With Combination or Sequence of Vemurafenib, cobImetinib, and atezolizuMab in Patients With High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma
NEOadjuvant Plus Adjuvant Therapy With Combination or Sequence of Vemurafenib, cobImetinib, and atezolizuMab in Patients With High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Drugs: Cobimetinib Oral Tablet, Vemurafenib Oral Capsule, Atezolizumab Injection
Study Phase: Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)
Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)
Enrollment Status: Withdrawn
Publish Date: September 14, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

130 Total Publications

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026

Frequently Asked Questions about Michele T. Del Vecchio

Is Michele T. Del Vecchio a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Michele T. Del Vecchio is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michele T. Del Vecchio participate in research or clinical trials?

Yes. Michele T. Del Vecchio has published 130 articles and abstracts on conditions like Melanoma. You can view a list of Michele T. Del Vecchio's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Del Vecchio's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile